BioNTech (BNTX) CFO awarded new performance share units and stock options

Rhea-AI Filing Summary

BioNTech SE Chief Financial Officer Ramon Zapata Gomez received new equity-based compensation. He was granted 15,103 Performance Share Units and 18,879 options, each tied to one ordinary share. The options carry an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, or cash.

Both the PSUs and options vest annually in equal installments over four years starting on the first anniversary of the grant. They become exercisable four years after the grant date and are subject to performance and other conditions, including share-price targets relative to the Nasdaq Biotechnology Index.

Insights

Equity compensation analyst

Routine equity grants align CFO pay with BioNTech share performance.

The CFO of BioNTech SE, Ramon Zapata Gomez, received 15,103 Performance Share Units and 18,879 stock options as compensation. The options have an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, or cash at the supervisory board’s election.

Both awards vest over four years, with annual installments starting one year after grant, and become exercisable after four years. PSU payouts depend on BioNTech’s share performance versus the Nasdaq Biotechnology Index, adding a market-based performance hurdle beyond simple time vesting.

These are non-cash, compensation-related acquisitions, not open-market purchases. They are typical for senior executives and do not, by themselves, signal a change in management’s outlook, though they further tie the CFO’s incentives to long-term share price performance.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Zapata Gomez Ramon

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	18,879	$0.00	--
Grant/Award	Performance Share Unit	15,103	$0.00	--

Holdings After Transaction: Option (right to buy) — 18,879 shares (Direct, null); Performance Share Unit — 15,103 shares (Direct, null)

Footnotes (1)

1. The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price. The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions. The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

Key Figures

Performance Share Units granted: 15,103 units Stock options granted: 18,879 options Option exercise price: EUR 89.38 per share +4 more

7 metrics

Performance Share Units granted 15,103 units Grant of PSUs to CFO; each tied to one ordinary share

Stock options granted 18,879 options Grant of options to CFO; each for one ordinary share

Option exercise price EUR 89.38 per share Exercise price for newly granted options, subject to 800% ADS cap

PSU underlying shares 15,103 shares Each PSU economically equivalent to one ordinary share

Option underlying shares 18,879 shares Each option relates to one ordinary share

Vesting period 4 years Awards vest annually in equal installments over four years

Relative performance benchmark Nasdaq Biotechnology Index PSU performance targets based on share price vs this index

Key Terms

Performance Share Unit, American Depositary Share, Nasdaq Biotechnology Index, exercise price, +1 more

5 terms

Performance Share Unit financial

"Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer"

A performance share unit (PSU) is a form of executive or employee pay that promises shares (or the cash value of shares) only if the company meets specific performance targets over a set period. Think of it like a bonus cheque that only arrives if the company hits agreed goals — it aligns managers’ rewards with business results and signals to investors how leadership is being incentivized to grow value over time.

American Depositary Share financial

"The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board."

An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.

Nasdaq Biotechnology Index financial

"performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index"

A stock index that tracks the performance of biotechnology companies listed on the NASDAQ stock exchange, combining many firms into a single measure of the sector’s movement. Think of it as a thermometer or basket that shows whether biotech stocks are generally rising or falling; investors use it to gauge sector health, compare individual holdings against the industry, and as the basis for funds that let you invest in the whole group at once.

exercise price financial

"The exercise price of this option is EUR 89.38."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option vests annually in equal installments over four years commencing on the first anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zapata Gomez Ramon

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ D-55131

(City) (State) (Zip)

GERMANY

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	(1)	05/12/2026		A		18,879		05/12/2030(2)	05/12/2036	Ordinary Shares(3)	18,879	$0	18,879	D
Performance Share Unit	$0	05/12/2026		A		15,103		05/12/2030(4)	05/12/2036	Ordinary Shares(4)	15,103	$0	15,103	D

Explanation of Responses:

1. The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price.

2. The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.

3. The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board.

4. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

Remarks:

	/s/ Humza Bokhari, Attorney-in-Fact	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did BioNTech (BNTX) grant to its CFO in this Form 4?

BioNTech granted CFO Ramon Zapata Gomez 15,103 Performance Share Units and 18,879 stock options. Each unit or option relates to one ordinary share, forming part of his long-term, equity-based compensation package tied to company performance and continued service over several years.

What is the exercise price of the BioNTech (BNTX) stock options granted to the CFO?

The options granted to the CFO have an exercise price of EUR 89.38 per underlying share. The filing notes this price may be adjusted so the trading price of an ADS on an exercise date does not exceed 800% of the grant date exercise price.

How do the Performance Share Units granted by BioNTech (BNTX) to its CFO vest?

The 15,103 Performance Share Units vest in equal annual installments over four years, starting on the first anniversary of the grant. They become exercisable four years after grant, contingent on meeting performance targets and the CFO’s continued service through each relevant vesting date.

What performance conditions apply to the BioNTech (BNTX) PSUs granted to the CFO?

The PSUs depend on BioNTech’s share performance relative to the Nasdaq Biotechnology Index. Vesting and exercisability require achieving specified performance targets based on that relative share price performance, along with the reporting person’s continued service through each vesting and exercisability date.

In what form can the BioNTech (BNTX) CFO’s options and PSUs be settled?

The options and Performance Share Units may be settled in ordinary shares, American Depositary Shares, and/or cash. The supervisory board or issuer chooses the settlement form, allowing flexibility between equity and cash while preserving the awards’ link to the economic value of BioNTech’s shares.

Are the BioNTech (BNTX) CFO’s new equity awards open-market purchases or compensation grants?

These transactions are compensation grants, not open-market purchases. The Form 4 uses code “A” for grant or award acquisition, reflecting routine equity-based compensation. They represent non-cash awards designed to align the CFO’s incentives with BioNTech’s long-term share price performance and market benchmarks.